BioSpecifics Technologies Cash Flow - Annual (NASDAQ:BSTC)

Add to My Stocks
$58.87 $0.84 (1.45%) BSTC stock closing price Sep 17, 2018 (Closing)

The BioSpecifics Technologies cash flow statement helps investors understand how well the company is managing its cash flows. Financials statements like the BioSpecifics Technologies income statement and BioSpecifics Technologies balance sheet show that the company has profits and debt, while the cash flow statement provides details of cash flow movments. The cash flow statement is essetial while conducting the BioSpecifics Technologies cash flow analysis and can be used to measure the operating performance of BioSpecifics Technologies compared to various industry peers like AQST stock and DERM stock. BSTC decrease in investments stood at a value of $-10.36M for the latest year 2017.

View details of BioSpecifics Technologies cash flows for latest & last 10 financial years
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow2.23M1.69M--------
Net Increase (Decrease) in Assets Liabilities-2.08M5.82M-0.5M--0.31M-2.31M-4.8M-1.29M4.15M-8.37M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net1.67M-2.53M---1.7M-2.53M1.9M1.49M1.47M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment----------
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments-10.36M-16.69M-20.1M-5.2M-1.84M-0.12M--0.81M-3.64M-
Other Cash Inflow (Outflow) from Investment Activities-----0.6M-1.5M----1.25M
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares-0.22M-0.33M1.02M1.31M-0.64M-0.88M-0.65M--6.26M
Issuance (Repayment) of Debt Securities----------
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities--3.8M1.93M--1.7M--1.43M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year4.76M5.13M9.81M5.62M3.38M3.19M2.47M3.95M3.49M-
Cash & Equivalents at Year End7.33M4.76M5.13M9.81M5.62M3.38M3.19M2.47M3.95M3.49M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

BioSpecifics Technologies stock comparison chart provides an easy way to compare the stock price with peers along with details of BioSpecifics Technologies stock price history.
The statement of cash flows can be categorized into three main sections:

  • BioSpecifics Technologies had a Net Change in Cash and Cash Equivalents of $2.57M for the latest year 2017. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the BioSpecifics Technologies stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: BioSpecifics Technologies reported a positive operating cash flow of $13.15M for 2017 and has seen a decrease from the previous year. Operating cash flow comes from main business activities. Investors look for positive cash flow from recurring operating activities.
  • Growth companies, typically most tech companies; spend heavily on investing activities and this figure stood at $-10.36M for BSTC stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $-0.22M for BioSpecifics Technologies.

Key Financial Ratios For BioSpecifics Technologies Cash Flow

FCF margin

Annual Cash Flow Statements For BioSpecifics Technologies Corp. Peers

Auxilium Pharma cash flow, Dermira cash flow, Lipocine cash flow, NephroGenex cash flow